Federal Circuit Rejects Biotech Company’s Rehearing Bid For DNA Patent Claims

( April 24, 2026, 12:20 PM EDT) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals rejected a gene therapy product maker’s petition for rehearing en banc, leaving in place a panel’s finding that a Delaware federal judge wrongly concluded that a patent’s claims involving genetically engineered cultured host cells containing a recombinant nucleic acid molecule were directed to a natural phenomenon....

Attached Documents

Related Sections